Adverse reactions to L-asparaginase in oncopediatric patients
Introduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmac...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | Brasil |
| Institución: | Fundação Oswaldo Cruz (FIOCRUZ) |
| Repositorio: | Vigilância Sanitária em Debate |
| Idioma: | portugués inglés |
| OAI Identifier: | oai:ojs.visaemdebate.incqs.fiocruz.br:article/1295 |
| Acceso en línea: | https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295 |
| Access Level: | acceso abierto |
| Palabra clave: | L-Asparaginase Leuginase Oncopediatrics Acute Lymphoblastic Leukemia Pharmacovigilance Oncopediátricos Leucemia Linfoblástica Aguda Farmacovigilância |
| Sumario: | Introduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy. |
|---|